Genflow Biosciences Signs MSA with Heureka Labs, Launching AI-Powered Partnership in Gene Therapy Research LONDON, UNITED KINGDOM / ACCESS Newswire / April 14, 2025 / Genflow Biosciences Plc (LSE:GENF ...

This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several ...

The company's latest venture involves the use of its proprietary Centenarian SIRT6 (cSIRT6) gene technology, which will be delivered using a non-viral vector specifically designed for targeting ...

Genflow Biosciences plc has announced a development program in ophthalmology focused on advancing a novel gene therapy leveraging its proprietary centenarian SIRT6 (cSIRT6).

Genflow will retain all IP rights under the MSA. Initial efforts will support the Company's lead candidate, GF-1002, a centenarian SIRT6-based gene therapy currently in preclinical evaluation and ...

This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several ...